Regenxbio Inc
F:RB0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Regenxbio Inc (RB0) under the Base Case is 10.68 EUR per share.
Compared with the current market price of 6.642 EUR, the stock appears
Undervalued by 38% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Regenxbio Does
Regenxbio is a biotechnology company that develops gene therapy medicines. It works by designing viral vectors that can deliver working genes into a patient’s cells, mainly for rare and serious diseases. The company’s business is built around research, clinical development, and licensing its gene therapy technology to drug makers that want to use it in their own programs.
- Headquarters
- United States of America US
- Employees
- 371
- IPO date
- Sep 17, 2015
Balance Sheet
Recent Events
Latest Earnings Call
REGENXBIO is nearing pivotal sura-vec readouts while advancing RGX-202 toward a full BLA filing, with both programs central to its preparations for potential commercialization.
Open the earnings call- EPS
- −$0.62
- Expected
- −$1.35
- Surprise
- +54.1%
- Stock, day of the call
- −4.3%
Regenxbio insiders made their first purchases in five years
Past 12 months
Continue RB0 Research
Decided on Regenxbio? Get an email when RB0 reaches the price you’d buy at. Free with an account.
Other Regenxbio listings
What is the Intrinsic Value of one RB0 stock?
The intrinsic value for
Regenxbio Inc (RB0) under the Base Case is 10.68 EUR.
Is RB0 stock undervalued or overvalued?
Compared with the current market price of 6.642 EUR, the stock appears Undervalued by 38% .